These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 37041624)

  • 1. Evaluating health information provided to kratom consumers by good manufacturing practice-qualified vendors.
    Hill K; Gibson S; Grundmann O; Smith KE; Ballard J; Stanciu CN
    Subst Abuse Treat Prev Policy; 2023 Apr; 18(1):21. PubMed ID: 37041624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing the quality of information provided on websites selling Kratom (Mitragyna speciosa) to consumers in Canada.
    Ng JY; Ans M; Marwaha A
    Subst Abuse Treat Prev Policy; 2021 Mar; 16(1):23. PubMed ID: 33741009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kratom use and mental health: A systematic review.
    Swogger MT; Walsh Z
    Drug Alcohol Depend; 2018 Feb; 183():134-140. PubMed ID: 29248691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlations of kratom (Mitragyna speciosa Korth.) tea bag preparations and reported pharmacological effects.
    Grundmann O; Hill K; Al Barzanji E; Hazrat NG; Kaur G; Negeve RE; Shade S; Weber S; Veltri CA
    J Ethnopharmacol; 2023 Dec; 317():116779. PubMed ID: 37364801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suspected Adulteration of Commercial Kratom Products with 7-Hydroxymitragynine.
    Lydecker AG; Sharma A; McCurdy CR; Avery BA; Babu KM; Boyer EW
    J Med Toxicol; 2016 Dec; 12(4):341-349. PubMed ID: 27752985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kratom policy: The challenge of balancing therapeutic potential with public safety.
    Prozialeck WC; Avery BA; Boyer EW; Grundmann O; Henningfield JE; Kruegel AC; McMahon LR; McCurdy CR; Swogger MT; Veltri CA; Singh D
    Int J Drug Policy; 2019 Aug; 70():70-77. PubMed ID: 31103778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Examining the Psychoactive Differences between Kratom Strains.
    Huisman G; Menke M; Grundmann O; Schreiber R; Mason N
    Int J Environ Res Public Health; 2023 Jul; 20(14):. PubMed ID: 37510657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring the self-reported motivations of kratom (
    Grundmann O; Veltri CA; Morcos D; Knightes D; Smith KE; Singh D; Corazza O; Cinosi E; Martinotti G; Walsh Z; Swogger MT
    Am J Drug Alcohol Abuse; 2022 Jul; 48(4):433-444. PubMed ID: 35389321
    [No Abstract]   [Full Text] [Related]  

  • 9. Kratom: Implications for Health Care Providers.
    Goldin D; Salani D; Mckay M
    J Psychosoc Nurs Ment Health Serv; 2019 Dec; 57(12):15-20. PubMed ID: 31774129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the hematological and clinical-chemistry parameters of kratom (Mitragyna speciosa) users in Malaysia.
    Singh D; Müller CP; Murugaiyah V; Hamid SBS; Vicknasingam BK; Avery B; Chear NJY; Mansor SM
    J Ethnopharmacol; 2018 Mar; 214():197-206. PubMed ID: 29248450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics of deaths associated with kratom use.
    Corkery JM; Streete P; Claridge H; Goodair C; Papanti D; Orsolini L; Schifano F; Sikka K; Körber S; Hendricks A
    J Psychopharmacol; 2019 Sep; 33(9):1102-1123. PubMed ID: 31429622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of urinary protein profile in regular kratom (
    Jasim RK; Hassan Z; Singh D; Boyer E; Gam LH
    J Addict Dis; 2022; 40(2):235-246. PubMed ID: 34747343
    [No Abstract]   [Full Text] [Related]  

  • 13. Acute Renal Insufficiency Associated With Consumption of Hydrocodone- and Morphine-Adulterated Kratom (Mitragyna Speciosa).
    LeSaint KT; Yin S; Sharma A; Avery BA; McCurdy CR; Waksman JC
    J Emerg Med; 2022 Jul; 63(1):e28-e30. PubMed ID: 35940982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Social Functioning of Kratom (Mitragyna speciosa) Users in Malaysia.
    Singh D; Müller CP; Vicknasingam BK; Mansor SM
    J Psychoactive Drugs; 2015; 47(2):125-31. PubMed ID: 25950592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changing trends in the use of kratom (Mitragyna speciosa) in Southeast Asia.
    Singh D; Narayanan S; Vicknasingam B; Corazza O; Santacroce R; Roman-Urrestarazu A
    Hum Psychopharmacol; 2017 May; 32(3):. PubMed ID: 28544011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding Kratom Use: A Guide for Healthcare Providers.
    Swogger MT; Smith KE; Garcia-Romeu A; Grundmann O; Veltri CA; Henningfield JE; Busch LY
    Front Pharmacol; 2022; 13():801855. PubMed ID: 35308216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experiences of Kratom Users: A Qualitative Analysis.
    Swogger MT; Hart E; Erowid F; Erowid E; Trabold N; Yee K; Parkhurst KA; Priddy BM; Walsh Z
    J Psychoactive Drugs; 2015; 47(5):360-7. PubMed ID: 26595229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kratom: The safe legal high?
    Coonan E; Tatum W
    Epilepsy Behav; 2021 Apr; 117():107882. PubMed ID: 33690067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kratom (Mitragyna speciosa) Validation: Quantitative Analysis of Indole and Oxindole Alkaloids Reveals Chemotypes of Plants and Products.
    Manwill PK; Flores-Bocanegra L; Khin M; Raja HA; Cech NB; Oberlies NH; Todd DA
    Planta Med; 2022 Aug; 88(9-10):838-857. PubMed ID: 35468648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Preliminary Inventory of Kratom
    Prevete E; Catalani V; Singh D; Kuypers KPC; Theunissen EL; Townshend HD; Banayoti H; Ramaekers JG; Pasquini M; Corazza O
    J Psychoactive Drugs; 2023 Sep; ():1-11. PubMed ID: 37702482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.